ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "proteomics"

  • Abstract Number: 0045 • ACR Convergence 2024

    Proteomic Analysis of the Rheumatoid Arthritis Citrullinome Reveals an Enrichment of Citrullinated Complement Proteins

    Khushali Trivedi1, Clarissa Klenke2, Jun Kim1, Jeba Atkia Maisha2, Alina Sememenko1, XIAOBO MENG2, Mario Navarrete1, Hani El-Gabalawy2 and Liam O'Neil2, 1University of Manitoba, Winnipeg, Canada, 2University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Citrullination is a key physiological process that drives autoantibody formation in Rheumatoid Arthritis (RA). This irreversible post-translational modification of the amino acid arginine is…
  • Abstract Number: 0909 • ACR Convergence 2024

    Identifying Predictive Serum Soluble Mediators Signatures Specific to ANA+ at Risk of SLE Individuals with Next Generation Proteomics

    Aleksandra Bylinska1, Miles Smith1, Rufei Lu1, Benjamin Jones2, Carla Guthridge1, Matthew Caleb Marlin1, Christian Wright3, Susan Macwana3, Wade DeJager3, Marci Beel3, Christopher Lessard1, Cristina Arriens1, Joan Merrill4, Judith James1 and Joel Guthridge1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma State University, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, 4Oklahoma Medical Research Foundation, Oklahoma City 73104, OK

    Background/Purpose: Multiple factors can predispose individuals to development of SLE, including the presence of African American ancestry, lupus-associated autoantibodies (ANAs), or some clinical manifestations of…
  • Abstract Number: 2245 • ACR Convergence 2024

    Clinical Efficacy and Molecular Cardiovascular Changes of Baricitinib in Biologic-naïve Patients with Rheumatoid Arthritis. Direct Comparative Analysis with TNF Inhibitors and Conventional DMARDs

    Chary Lopez-Pedrera1, Laura Muñoz-Barrera2, Rafaela Ortega-Castro3, Sagrario Corrales2, Jerusalén Calvo4, Concepción Aranda-Valera5, María Lourdes Ladehesa-Pineda1, Pilar Font2, Ismael Sánchez Pareja2, Elena Moreno-Caño5, María Carmen Ábalos-Aguilera6, Christian Merlo-Ruiz6, Mª Angeles Aguirre-Zamorano7, Tomás Cerdó2, Nuria Barbarroja2, Carlos Perez-Sanchez2 and Alejandro Escudero-Contreras2, 1IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, 2IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 3Hospital Reina Sofía, Cordoba, Andalucia, Spain, 4IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 5IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain, 6IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Spain, 7IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain

    Background/Purpose: The main objective of this study was to conduct extensive clinical and molecular analyses to accurately characterize the specific effects of Baricitinib (4 mg/day)…
  • Abstract Number: 0113 • ACR Convergence 2024

    Plasma Proteomics Analysis Identifies Thromboinflammatory Signature Associated with Clinical Antiphospholipid Syndrome: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry

    Alexander Pine1, Vittorio Pengo2, Savino Sciascia3, Nina Kello4, Rosario Lopez Pedrera5, H Michael Belmont6, David Branch7, Laura Andreoli8, Michelle Petri9, Ricard Cervera10, Jason Knight11, Pierluigi Meroni12, Hannah Cohen13, Rohan Willis14, Maria Laura Bertolaccini15, Alfred Lee16, Doruk Erkan17 and Anish Sharda16, 1Yale School of Medicine/VA Connecticut, West Haven, CT, 2Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, 3University of Turin, Torino, Turin, Italy, 4Northwell Health, Brooklyn, NY, 5IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 6NYU School of Medicine, New York, NY, 7University of Utah and Intermountain Healthcare, Salt Lake City, UT, 8University of Brescia, Brescia, Italy, 9Johns Hopkins University School of Medicine, Timonium, MD, 10Hospital Clinic de Barcelona, Barcelona, Spain, 11University of Michigan, Ann Arbor, MI, 12IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, 13University College London Hospitals NHS Foundation Trust, London, United Kingdom, 14University of Texas Medical Branch, Galveston, TX, 15King's College London, London, United Kingdom, 16Yale School of Medicine, New Haven, CT, 17Hospital for Special Surgery, New York, NY

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thromboembolic and obstetric morbidity arising via a model of immunothrombosis. Patients may present with thrombotic (tAPS),…
  • Abstract Number: 0961 • ACR Convergence 2024

    Multi-omics Study of Systemic Sclerosis Immunoglobulins G Effects on Endothelial Cells: A Distinct Profile in Anti-Topoisomerase I Positive Patients

    Aurélien Chepy1, Solange Vivier2, Abderrahmane Elhannani2, Fabrice Bray3, Clément Chauvet4, Martin Figeac5, Lucile Guilbert4, Eric HACHULLA6, Christian Rolando3, Sylvain Dubucquoi4, David Launay4 and Vincent sobanski4, 1Univ. Lille, Inserm, CHU Lille, U1286—INFINITE—Institute for Translational Research in Inflammation, Lille, France., Lille, Nord-Pas-de-Calais, France, 2Univ. Lille, Inserm, CHU Lille, U1286—INFINITE—Institute for Translational Research in Inflammation, Lille, France., Lille, France, 3Univ. Lille, CNRS, USR 3290 - MSAP - Miniaturisation pour la Synthèse l’Analyse et la Protéomique, F-59000 Lille, France, Lille, France, 4Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France., Lille, France, 5Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, F-59000 Lille, France, Lille, France, 6CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., LILLE, France

    Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous connective tissue disease characterized by autoimmunity, fibrosis and vasculopathy. Antinuclear antibodies (ANA) are strong diagnostic and prognosis biomarkers…
  • Abstract Number: 2263 • ACR Convergence 2024

    The Potential Use of Circulating Extracellular Vesicles for Improved Diagnosis and Therapy in Rheumatic Inflammatory/autoimmune Diseases: Proof of Concept Studies

    Gilad Halpert1, Ori Moskovitch2, Linoy Israel2, Eri Govrin2, Boris Gilburd2, Ori Segal2, Adi Anaki3, Tal Caller2, Daniel Yechiali2, Shlomo Segev2, Omer Gendelman4, Abdulla Watad5, Ruty Mehrian-Shai2, Rachella Popovtzer3 and Howard Amital6, 1CAHIM SHEBA MEDICAL CENTER, Tel Hashomer, Israel, 2Sheba Medical Center, Ramat-Gan, Israel, 3Bar Ilan University, Ramat-Gan, Israel, 4Sheba Medical Center, Ramat Gan, Israel, 5Tel Hashomer Medical Center, Ramat Gan, Israel, 6Sheba Medical Center, Tel-Hashomer, Israel, Ramat Gan, Israel

    Background/Purpose: Many patients with rheumatic conditions do not completely respond or are refractory to biological therapy. Therefore, there are unmet medical needs in the treatment…
  • Abstract Number: 0127 • ACR Convergence 2024

    Unsupervised Machine Learning Improves Clinical Stratification and Prognostic Evaluation for Antiphospholipid Syndrome: A Large Cohort Study from China

    Chen Chen1, Ao Zhang2, Jianhui Cheng3, Zhongqiang Yao4, Juan Meng5, Yilu Qin6, Qingyi Lu1, Yufei Li1, Xiangjun Liu1, Tianhao Li7, Chao Hou7, Yundi Tang1, Hongjiang Liu8, Ning Xu1, Sai Dong1, Xinxin Li3, Fangmin Xu2, Jianping Guo1 and Chun Li1, 1Peking University People's Hospital, Beijing, China, 2Beijing University of Posts and Telecommunications, Beijing, China, 3State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China (People's Republic), 4Peking University Third Hospital, Beijing, China, 5Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China, 6Affiliated Xinxiang Central Hospital of Xinxiang Medical University, Xinxiang, China (People's Republic), 7Peking University Health Science Center, Beijing, China, 8West China Hospital, Sichuan University, Chengdu, China (People's Republic)

    Background/Purpose: Antiphospholipid syndrome (APS) is a complex disease characterized by the presence of anti-phospholipid antibodies (aPLs). Its significant clinical heterogeneity brings clinical and therapeutical challenges.…
  • Abstract Number: 1383 • ACR Convergence 2024

    Proteomics and Machine Learning Accurately Predict Clinical Response to Etanercept Therapy in Patients with Rheumatoid Arthritis

    Huaqun Zhu1, Gong cheng1, yingni Li1, Yun Li1, Feng Sun1, Hongyan Wang1, Qinqin li2, Zhilun Li3, Ru Li4 and Zhanguo Li5, 1Peking University People's Hospital, Beijing, China, 2Sansheng Guojian Pharmaceutical (Shanghai) Company, Shanghai, China (People's Republic), 3Sansheng Guojian Pharmaceutical (Shanghai) Company, Shanghai, 4Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China, 5People’s Hospital Peking University Health Sciences Centre, Beijing, China

    Background/Purpose: Our study aimed to use machine-learning approaches to characterize the proteomics profiles of patients who were inadequate responders to Etanercept (ETN-IRs) and develop an…
  • Abstract Number: 2333 • ACR Convergence 2024

    Unveiling New Molecular Signatures in Psoriatic Arthritis Using Comprehensive Proteomic Analysis of Peripheral Mononuclear Cells

    Eduardo Martin-Salazar1, Iván Arias-de la Rosa2, Laura Cuesta-López3, María Lourdes Ladehesa-Pineda4, Miriam Ruiz-Ponce3, Antonio Barranco3, Maria Angeles Puche-Larrubia5, Carlos Perez-Sanchez3, Yas Hanaee3, Pedro Ortiz-Buitrago3, Rosario Lopez Pedrera3, Alejandro Escudero-Contreras3, Eduardo Collantes-Estevez6, Clementina López Medina7 and Nuria Barbarroja3, 1IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordonba, Spain, 2Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, 3IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 4IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, 5Reina Sofía University Hospital, Cordoba, Spain, 6Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba 14012, Spain, 7Reina Sofia University Hospital, Cordoba, Spain

    Background/Purpose: Diagnosing psoriatic arthritis (PsA) is challenging, underscoring the importance of discovering novel biomarkers through proteomics for early and accurate detection. Molecular clustering can elucidate…
  • Abstract Number: 0151 • ACR Convergence 2024

    Immunoproteomic Profiling of Antibodies in Autoimmune Diseases

    Choa Yun1, Ji Qiu2, M. Constanza Camargo3, Lusheng Song2, Joshua LaBaer2, Hyokyoung G. Hong3, Eric A. Engels3, Maddy Edie-Booker4, Adam Schiffenbauer5, Lisa Rider6, Frederick Miller7, Sarfaraz Hasni5, Blake M. Warner5, Mārcis Leja8 and Minkyo Song9, 1National Institute on Aging, Rockville, MD, 2Arizona State University, Tempe, 3National Cancer Institute, Rockville, 4National Institute on Aging, Baltimore, MD, 5NATIONAL INSTITUTES OF HEALTH, Bethesda, MD, 6NIEHS, NIH, Garrett Park, MD, 7NIH, NIEHS, Chapel Hill, NC, 8University of Latvia, Rīga, Latvia, 9National Institutes on Aging, Baltimore, MD

    Background/Purpose: Prior research has investigated a limited range of candidate markers within individual autoimmune diseases. This study aimed to identify specific and common autoantibodies and…
  • Abstract Number: 1463 • ACR Convergence 2024

    Investigation of the Cardiometabolic-related Mechanism of Action of Apremilast Through Plasma Proteomics Profiling of Patients with Psoriasis or Psoriatic Arthritis from Three Phase 3 Studies

    A. Francesca Setiadi1, Maggie Burhans2, Xuguang Hu2, Stephen Colgan3, Kim Notari2, Marcia C. Teixeira dos Santos2, Apostolos Kontzias2, Sue Cheng2 and Nehal Mehta4, 1Amgen Inc., South San Francisco, CA, 2Amgen Inc., Thousand Oaks, CA, 3Amgen, Halton Hills, ON, Canada, 4The George Washington University School of Medicine, Washington, DC

    Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are associated with higher rates of obesity and cardiometabolic complications. Apremilast (APR) is an inhibitor of phosphodiesterase 4,…
  • Abstract Number: 2379 • ACR Convergence 2024

    Causal Proteomics-Assisted Machine Learning Model Enhances Flare Risk Prediction in Systemic Lupus Erythematosus

    Liying Chen1, Ou Deng2, Ruichen Cong2, Dingqi Lu3, Ting Fang1, Mei Chen1, Runrun Zhang4 and Xinchang Wang3, 1Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China (People's Republic), 2Graduate School of Human Sciences, Waseda University, Mikajima, Japan, 3Department of Rheumatology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China (People's Republic), 4The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China (People's Republic)

    Background/Purpose: Objectives: Systemic lupus erythematosus (SLE) is an autoimmune disease marked by unpredictable flares. However, no flare risk prediction model has been developed for Asian…
  • Abstract Number: 0383 • ACR Convergence 2024

    Identification of Protein Biomarkers in Tear Fluid of Children with Uveitis That Distinguishes the Ocular Inflammatory State

    Ilaria Maccora1, hermine brunner2, Mekibib Altaye3, Alexandra Duell3, Wendy Haffey4, Megan Quinlan-Waters3, Alyssa Sproles5, Sherry Thornton5, Virginia Miraldi Utz3, Kenneth Greis4 and sheila Angeles-Han6, 1?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, 2Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Proteomics and Mass Spectrometry, University of Cincinnati, Cincinnati, OH, Cincinnati, OH, 5Cincinnati Children's Hospital, Cincinnati, 6Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Vision loss occurs in 50% of children with chronic anterior uveitis (CAU). Lack of symptoms and overt ocular signs of inflammation may lead to…
  • Abstract Number: 1571 • ACR Convergence 2024

    Growth Differentiation Factor 15 Is a Serum Biomarker and Pathogenic Factor of Progressive Fibrosis in Systemic Sclerosis

    Vishal Kakkar1, Sunhwa Kim2, Yingtao Bi3, Christopher Wasson1, Stefano Di Donato4, Rebecca Ross5, Marco Di Battista6, Enrico De Lorenzis7, Thierry Sornasse2 and Francesco Del Galdo1, 1University of Leeds, Leeds, United Kingdom, 2AbbVie, South San Francisco, CA, 3Abbvie, Worcester, MA, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 5Medicine and Health, University of Leeds, Leeds, United Kingdom, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Pisa, United Kingdom, 7Catholic University of the Sacred Heart, Roma, Rome, Italy

    Background/Purpose: In systemic sclerosis (SSc), interstitial lung disease (ILD) remains the leading cause of mortality. A decline in forced vital capacity (FVC) is considered a…
  • Abstract Number: 2487 • ACR Convergence 2024

    Comparing Circulating Protein Profiles in Patients with Active Myeloperoxidase (MPO) vs Proteinase-3 (PR3) Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis

    Colebrook Johnson1, David O'Dea1, Natalie Atallah1, Gary Reynolds1, Bohang Jiang1, Shruthi Srivatsan1, Zachary Williams1 and Zachary Wallace2, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Newton, MA

    Background/Purpose: ANCA type (e.g., PR3-, MPO-ANCA) may be a better way to subgroup patients with ANCA-associated vasculitis (AAV) than phenotype (e.g., granulomatosis with polyangiitis [GPA]).…
  • 1
  • 2
  • 3
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology